Other Clinical Trial - A Dose Finding Study of AEB071 Assessing Psoriasis

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). The treatment free Follow-up Period is designed to provide additional safety data and information on disease recurrence after the last dose of the study drug.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03424629` - Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis	Phase 1

NCT number	NCT00885196
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	April 2009

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms